We helped Abbott leadership dig deeply into each major business at the product and market-segment levels to assess the future economic profit improvement potential of each business.
This assessment produced an explicit value improvement agenda that involved improving underperforming businesses, like diagnostics or diabetes, increasing investment in advantage businesses like nutrition, and spinning off businesses like pharmaceuticals that could be better managed as separately operated and traded corporations like Abbvie.
As with other clients, this focused and systematically executed value-improvement program has resulted in superior shareholder returns and a sustainable reinvestment advantaged that strengthens the company going forward.